

Zoryve® (roflumilast) – Expanded indication

- On October 6, 2023, <u>Arcutis Biotherapeutics announced</u> the FDA approval of <u>Zoryve (roflumilast)</u>, for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.
 - Zoryve was previously approved for the same indication in patients 12 years of age and older.
- The approval of Zoryve for the expanded indication was supported by data from two 8-week, vehicle-controlled safety and efficacy trials which included 18 pediatric subjects 6 to 17 years of age, of whom 11 received Zoryve. Use of Zoryve in pediatric patients 6 to less than 12 years of age is also supported by data from one 4-week, open-label, safety and pharmacokinetic study which included 20 pediatric subjects 6 to less than 12 years of age.
- Zoryve should be applied to the affected areas once daily and rubbed in completely.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.